Continuous Bio-Manufacturing Skid Market Expected To Reach $3.72 Billion By 2030 As Growth Accelerates At 13.3% CAGR
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Continuous Bio-Manufacturing Skid Market Expected To Reach $3.72 Billion By 2030 At 13.3% CAGR
In recent years, the continuous bio-manufacturing skid market size has undergone rapid expansion. Its value is projected to increase from $1.99 billion in 2025 to $2.26 billion in 2026, representing a compound annual growth rate (CAGR) of 13.6%. Historical growth can be explained by rising biologics production volumes, an early industry shift from batch processing toward continuous methods, greater adoption of modular manufacturing concepts, the expansion of vaccine and enzyme production facilities, and a growing need for flexible manufacturing setups.
The continuous bio-manufacturing market is projected to experience rapid expansion over the coming years, with its valuation anticipated to reach $3.73 billion by 2030, reflecting a compound annual growth rate (CAGR) of 13.3%. This forecasted growth is driven by factors such as the increasing implementation of fully continuous biologics production processes, heightened investment in sophisticated bioprocess automation, a growing need for fast scale-up capabilities, the expansion of cell and gene therapy manufacturing, and a stronger emphasis on cost-efficient biologics production. Key trends shaping this period include the rising adoption of continuous and integrated bioprocessing skids, greater demand for modular and plug-and-play manufacturing systems, more widespread use of real-time process monitoring and control, the growth of single-use continuous biomanufacturing platforms, and an intensified focus on process efficiency and throughput.
Download A Free Sample Report For Comprehensive Market Insights:
Continuous Bio-Manufacturing Skid Market Development Factors: Which Trends Are Supporting Demand?
The continuous bio-manufacturing skid market is anticipated to expand due to the rising need for biopharmaceuticals. These are therapeutic products derived from biological sources like proteins, nucleic acids, or living cells, designed to treat, prevent, or diagnose illnesses. This growing demand is largely fueled by the increasing occurrence of chronic and genetic conditions, which require advanced biologic therapies for effective care and management. Continuous bio-manufacturing skids improve the production of biopharmaceuticals by facilitating streamlined, automated, and scalable processes that boost efficiency, consistency, and speed in developing complex treatments. For example, Cardinal Health Inc., a U.S.-based healthcare firm, reported in January 2023 that the U.S. had 40 FDA-approved biosimilar products by 2023, with 25 available on the market. This compares to 33 FDA-approved biosimilars as of January 2022, of which 21 were commercially accessible. Consequently, the escalating demand for biopharmaceuticals is fueling growth in the continuous bio-manufacturing skid market.
Continuous Bio-Manufacturing Skid Market Segment Landscape: Which Areas Lead Market Development?
The continuous bio-manufacturing skid market covered in this report is segmented –
1) By Product Type: Single-Use Skids, Multi-Use Skids, Modular Skids
2) By Process: Upstream, Downstream, Integrated
3) By Application: Biopharmaceutical Production, Vaccine Manufacturing, Enzyme Production, Cell And Gene Therapy, Other Applications
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Institutes, Other End-Users
Subsegments:
1) By Single-Use Skids: Perfusion Bioreactor Skid, Tangential Flow Filtration Skid, Chromatography Skid, Buffer Preparation Skid
2) By Multi-Use Skids: Fed-Batch Bioreactor Skid, Downstream Purification Skid, Ultrafiltration Skid, Viral Inactivation Skid
3) By Modular Skid: Plug And Play Bioreactor Skid, Integrated Downstream Skid, Automated Sampling Skid, Real-Time Monitoring Skid
Continuous Bio-Manufacturing Skid Market Transformation Trends: Which Innovations Are Driving Change?
Major players in the continuous bio-manufacturing skid sector are concentrating on advancing innovative tools, including next-gen biologics production platforms, aimed at boosting efficiency, expandability, and product excellence. These advanced next-generation platforms represent sophisticated systems that support fully integrated, ongoing biologic manufacturing with live oversight, enhanced productivity, and steady output quality. For example, in October 2024, Enzene Biosciences Ltd., an Indian contract development and manufacturing organization, unveiled EnzeneX 2.0 at CPHI Milan 2024, which is the newest iteration of their fully integrated continuous manufacturing technology for biologics. This proprietary system allows seamless, unbroken processing from perfusion through to final drug substance production. By employing high-yield clones and optimized culture media, it increases output, raises target protein concentrations, and reduces variation between production batches. Additionally, the setup incorporates process analytical technology for real-time monitoring and control, delivering consistent quality and operational effectiveness, while providing a potential reduction of up to 50% in production expenses per gram. These platforms enable scalable, cost-efficient biologics production adaptable to various therapeutic modalities and media formulations.
Continuous Bio-Manufacturing Skid Market Industry Leaders And Market Competition
Major companies operating in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, CPi Biotech Inc.
Access The Complete Continuous Bio-Manufacturing Skid Market Report:
Continuous Bio-Manufacturing Skid Market Regional Analysis And Leading Geography
North America was the largest region in the continuous bio-manufacturing skid market in 2025. The regions covered in the continuous bio-manufacturing skid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
